Therefore, we aimed to evaluate whether the progression of ccRCC is affected by a β3-AR agonist, and to explore its potential role in tumor initiation using metastatic orthotopic murine RCC models through the perspective of regulation of TIME and PAT browning. This evidence concerns the gene ADRB3 and nonpapillary renal cell carcinoma.